| NCT ID | NCT05920330 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ohio State University |
| Condition | Nasal Obstruction |
| Study Type | INTERVENTIONAL |
| Enrollment | 330 participants |
| Start Date | 2023-01-25 |
| Primary Completion | 2027-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 330 participants in total. It began in 2023-01-25 with a primary completion date of 2027-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
About 13% of US adults, some 30 million people, suffer from nasal sinus disease. Although nasal obstruction and smell loss are two of the major symptoms of the disease that are crucial to disease management, currently there is a lack of clinical tools to effectively evaluate the mechanisms contributing to these symptoms. The proposed study aims to develop novel clinical tools to better evaluate and relieve patients' nasal obstructive symptoms and to enable patients and clinicians to make more informed, personalized decisions regarding treatment strategy.
Eligibility Criteria
Inclusion Criteria: 1. Smell Loss complaints 2. Nasal Obstruction Exclusion Criteria: 1. Congenital olfactory losses 2. Nasal polyps, blocking the olfactory cleft 3. Significant atrophy 4. Cystic fibrosis 5. Wegeners or any other connective tissue disorder 6. Head trauma
Contact & Investigator
Kai Zhao, Ph.D
PRINCIPAL INVESTIGATOR
Associate Professor
Frequently Asked Questions
Who can join the NCT05920330 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Nasal Obstruction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05920330 currently recruiting?
Yes, NCT05920330 is actively recruiting participants. Contact the research team at Veronica.Formanek@osumc.edu for enrollment information.
Where is the NCT05920330 trial being conducted?
This trial is being conducted at Columbus, United States.
Who is sponsoring the NCT05920330 clinical trial?
NCT05920330 is sponsored by Ohio State University. The principal investigator is Kai Zhao, Ph.D at Associate Professor. The trial plans to enroll 330 participants.